

Title: Mass cytometric functional profiling of acute myeloid leukemia defines cell cycle and immunophenotypic properties that correlate with known responses to therapy

Authors: Behbehani et al

Publication: Cancer Discovery, June 2015

Data Source: Supplementary Table 2

Antigen	Conjugate	Clone	Concentration	Manufacturer	Panel	CV	Analyses
CD3	In-113	UCHT1	2 µg/mL	Biolegend	A & B	11.7%	S, V, B
CD45	In-115	HI30	2 µg/mL	Biolegend	A & B	14.1%	S, V, B
CD45RA	La-139	HI100	1.5 µg/mL	Biolegend	A	14.2%	
p-RPS6 (S235/36)	La-139, Yb-175	N7-548	1 µg/mL	BD Biosciences	B (La-139) A (Yb-175)	20.2% 14.3%	
CD133	Pr-141	AC133	3 µg/mL	Milteney	A	36.5%	
pATM (S1981)	Pr-141	10H11.E12	2 µg/mL	Millipore	B	16.7%	
CD7	Nd-142	M-T701	2 µg/mL	BD Biosciences	A & B	24.1%	S, V, B
CD71	Nd-143	R17217	2 µg/mL	eBiosciences	A & B	12.4%	S
CD235	Nd-144	HIR2	6 µg/mL	Biolegend	A & B	9.6%	S, V, B
CD47	Nd-145	B6H12	1.5 µg/mL	BD Biosciences	A	12.8%	
pAkt (S473)	Nd-145	D9E	2 µg/mL	CST	B	11.3%	
p21	Nd-146	SXM30	2 µg/mL	BD Biosciences	A	13.9%	
Histone 3 (K9ac)	Nd-146	C511B	0.5 µg/mL	CST	B	17.8%	
CD56	Sm-147	NCAM16.2	1.5 µg/mL	BD Biosciences	A & B	13.3%	V, B
CD34	Nd-148	8G12	3 µg/mL	BD Biosciences	A & B	16.4%	S, V, B
CD90	Sm-149	5E10	3 µg/mL	Biolegend	A	16.4%	
cMyc	Sm-149	D84C12	1 µg/mL	CST	B	16.2%	
CD117	Nd-150	104D2	1 µg/mL	Biolegend	A & B	27.2%	S, V, B
CD123	Eu-151	6H6	1 µL per 100 µL	DVS	A & B	15.7%	S, V, B
CD33	Sm-152	P67.6	1.5 µg/mL	BD Biosciences	A & B	15.1%	S, V, B
HLA-DR	Eu-153	L243	2 µg/mL	Biolegend	A & B	12.3%	S
Cyclin A	Sm-154	BF683	2 µg/mL	BD Biosciences	A	10.4%	
pMAPKAPK2 (T334)	Sm-154	27B7	2 µg/mL	CST	B	21.5%	
Cyclin B1	Gd-156	GNS-1	3 µg/mL	BD Biosciences	A	9.8%	
pSTAT3 (Y705)	Gd-156	4	2 µg/mL	BD Biosciences	B	17.2%	
PCNA	Gd-157	PC10	0.5 µg/mL	BD Biosciences	A	15.9%	
pSTAT5 (Y694)	Gd-157	47	2 µg/mL	BD Biosciences	B	13.9%	
Ki-67	Gd-158	SolA15	1 µg/mL	eBiosciences	A & B	12.7%	
CD38	Tb-159	HIT2	1 µg/mL	Biolegend	A & B	11.9%	S, V, B
CD14	Gd-160	M5E2	2 µg/mL	Biolegend	A & B	15.4%	S, V, B
CD16	Dy-161	3G8	2 µg/mL	Biolegend	A & B	13.1%	S, V, B
CD11b	Dy-162	ICRF44	2 µg/mL	Biolegend	A & B	16.1%	S, V, B
CD15	Dy-164	W6D3	3 µg/mL	Biolegend	A & B	15.3%	S, V, B
p-pRb (S807/811)	Ho-165	J112-906	0.75 µg/mL	BD Biosciences	A	20.7%	
pNF-κB (p65) (S529)	Ho-165	K10-895.12	2 µg/mL	BD Biosciences	B	16.1%	
CD321	Er-166	WK9	3 µg/mL	eBiosciences	A & B	13.9%	S, V, B
CD99	Er-167	HCD99	0.5 µg/mL	Biolegend	A & B	24.2%	V, B
CD13	Er-168	L138	2 µg/mL	BD Biosciences	A	9.9%	
pERK 1/2 (T202/Y204)	Er-168	G2/D13	2 µg/mL	CST	B	10.4%	
cleaved- PARP(D214)	Yb-171	F21-852	1 µg/mL	BD Biosciences	A & B	N/A	
CD10	Yb-172	HI10a	3 µg/mL	Biolegend	A & B	12.5%	S, V, B
CD19	Yb-173	H1B19	2 µg/mL	BD Biosciences	A & B	9.9%	S, V, B
CD20	Yb-174	2H7	2 µg/mL	Biolegend	A & B	13.2%	S, V, B
pSMAD1/5 (S463/S465)	Yb-175	41D10	3 µg/mL	CST	B	N/A	
pHistone H3(S28)	Yb-176	HTA28	0.5 µg/mL	Biolegend	A	18.5%	
pCREB (S133)	Yb-176	87G3	1.5 µg/mL	CST	B	9.7%	